Draft — Africa HealthTech ExCon Accelerator 2026

MOTIVATION LETTER

The Africa HealthTech ExCon Accelerator 2026 exists to scale ventures that fix broken points in African healthcare delivery. The broken point I am fixing is medication access and safety in Nigeria, where fewer than 30 percent of patients with chronic conditions adhere to their prescribed regimens, and where counterfeit or substandard drugs account for an estimated one in five medicines in circulation. My venture, a regulatory-aware telepharmacy platform, directly addresses both failures through a model that only a licensed pharmacist could build and only a computational researcher could scale.

I hold a B.Pharm from the University of Ibadan with a 5.1/7.0 CGPA and a current license from the Pharmacists Council of Nigeria. I have worked as a clinical pharmacist at Ramset Pharmacy and as National Product Manager at Synthcare, where I managed pharmaceutical supply operations across Nigerian markets. That combination means I know the regulatory pathway for pharmacy practice in Nigeria from the inside, including the state-by-state licensing requirements, the controlled-substance reporting obligations, and the inspection regimes that a telepharmacy venture must satisfy. Most digital health startups treat regulation as an afterthought; I treat it as the moat.

The platform itself is early-stage, pre-revenue, and honest about that status. What exists today is a working prototype of the medication management core: a Supabase-backed patient record system, a pharmacist-in-the-loop verification workflow, and a delivery logistics module designed for the last-mile realities of Nigerian cities. The AI layer, which flags drug-drug interactions and dose errors using structured pharmaceutical data, is built on the same computational infrastructure I have used in my published research, including four independent DuckDB-based data pipelines and self-hosted LLM serving for clinical document processing. I am not a founder who needs to hire engineers to understand the product; I am the engineer who built the prototype.

The accelerator's focus on scalable, impact-driven healthtech across African markets matches this venture's geography and ambition. Nigeria has over 200 million people and fewer than 60,000 licensed pharmacists, a ratio that makes pharmacist-led telemedicine a necessity rather than a convenience. The model scales across other African markets with similar pharmacist shortages, including Ghana and Kenya, where the regulatory frameworks for telepharmacy are actively being drafted. I am applying to this programme specifically because its emphasis on early-stage ventures with regulatory awareness and AI-driven patient safety aligns with the two assets I actually have: a pharmacist license and a computational research record.

The commitment is demonstrated, not claimed. I have spent four years building computational models in addiction neuroscience and protein ML, published three sole-authored preprints currently under peer review, and built a brain-circuit simulation engine with 62 passing tests. I am enrolled in the M.Sc. Digital Health programme at the Hasso Plattner Institute in Potsdam, Germany, starting Winter Semester 2026/27, which gives me access to European digital health research networks while I build this venture for African markets. The accelerator's network, mentorship, and investor connections are the missing pieces between a working prototype and a deployed service.

RESEARCH STATEMENT

The venture I am bringing to the Africa HealthTech ExCon Accelerator 2026 is a regulatory-aware telepharmacy platform for Nigeria and, subsequently, other African markets. This is the single venture in my portfolio that matches the accelerator's stated focus on digital health, telemedicine, pharmaceutical innovation, and scalable impact. My other research lines, including the CCT model in addiction neuroscience and the TOPOLOGIX protein-language-model work, are independent computational research projects with different funders and different goals. They are not this venture, and I am not presenting them as such. What they contribute is methodological credibility: the same Bayesian calibration, data pipeline engineering, and rigorous validation discipline I apply to research papers will apply to the platform's clinical safety systems.

The problem is specific and quantified. Nigeria has approximately 60,000 licensed pharmacists serving over 200 million people, a ratio of roughly one pharmacist per 3,500 patients, far below the World Health Organization's recommended threshold. Chronic disease burden is rising, with hypertension and diabetes prevalence estimated at 35 percent and 7 percent of adults respectively, and medication adherence rates in Nigerian primary care settings are frequently reported below 40 percent. Simultaneously, the National Agency for Food and Drug Administration and Control estimates that a significant fraction of medicines in circulation are substandard or falsified. A telepharmacy platform that connects patients to licensed pharmacists for verification, counseling, and delivery addresses all three failures: access, adherence, and drug quality assurance.

The current stage is early and I will not overstate it. The prototype includes a patient-facing medication request interface, a pharmacist dashboard for verification and counseling, a delivery logistics module, and a structured pharmaceutical database for interaction checking. The AI safety layer, which flags potential drug-drug interactions and dose errors, is built on the same computational stack I use in research: Python, DuckDB for structured data pipelines, and self-hosted LLM serving for processing clinical documents. The system is designed to be regulatory-aware from the ground up, meaning it logs every pharmacist action, maintains an append-only audit trail, and generates the reports required for Nigerian pharmacy board inspections. This is not a feature added later; it is the architecture.

The validation status is honest: the prototype works in controlled testing, but it has not yet been deployed with real patients or real prescriptions. The next six months, which this accelerator would fund and mentor, are focused on a pilot with a single partner pharmacy in Lagos, covering 200 to 300 patients with hypertension or diabetes, measuring adherence rates, pharmacist response times, and patient satisfaction against baseline published data. The pilot design is pre-registered, with primary endpoints specified in advance, consistent with the methodology I use in my research. I will report the results regardless of outcome.

The scalability argument rests on the pharmacist shortage itself. The platform does not replace pharmacists; it multiplies their reach. A single pharmacist can counsel and verify prescriptions for patients across an entire city, rather than only those who physically visit the pharmacy. The regulatory moat is that I hold the license, I know the inspection regime, and I have built the audit infrastructure to satisfy it. The business model is a per-prescription fee paid by the patient or their health insurance, with a target gross margin of 30 to 40 percent once delivery logistics reach scale. The accelerator's emphasis on healthtech ventures with clear paths to scale across African markets is precisely the support this venture needs at this stage.

ESSAY: INNOVATION AND DIFFERENTIATION

The innovation is a new distribution of an existing, regulated professional service, enabled by software that treats regulatory compliance as a core feature rather than an add-on. Nigeria has licensed pharmacists and it has patients who need their expertise. The gap is physical distance and the absence of a trusted digital channel. My platform closes that gap with a pharmacist-in-the-loop model: every prescription is verified by a licensed pharmacist before any medication is dispensed, every interaction is logged to an append-only audit trail, and every delivery is tracked. This is differentiated from the typical Nigerian healthtech startup, which often builds a marketplace for medicines without a pharmacist actually reviewing the prescription, or a telemedicine platform where the physician prescribes but the pharmacy step is unmanaged.

The AI layer is the second differentiator. I am building a structured interaction-checking system that flags drug-drug interactions, dose errors, and contraindications using a curated pharmaceutical database, with the pharmacist as the final decision-maker. This is the same discipline I apply in my research, where I have built Bayesian-calibrated models with literature-elicited priors from an 1,847-record screen and reported falsified hypotheses directly rather than reframing them. The AI is a decision-support tool with a human accountable for every clinical decision.

The third differentiator is the regulatory moat. I hold a current Pharmacists Council of Nigeria license. I have worked as a clinical pharmacist and as a National Product Manager at Synthcare, where I managed pharmaceutical supply operations. I know the inspection regimes, the controlled-substance reporting requirements, and the state-level licensing variations. Most founders would need to hire a pharmacist consultant to navigate this; I am the pharmacist.

ESSAY: TRACTION AND COMMITMENT

The traction is honest and early-stage. The prototype is built and functional. The regulatory analysis is complete for Lagos State, with a clear pathway for expansion to other Nigerian states. The founder commitment is demonstrated by four years of independent computational research, including three sole-authored preprints under peer review, a brain-circuit simulation engine with 62 passing tests, and a pre-registered replication study that settled a question the published literature had never actually tested. I am enrolled in the M.Sc. Digital Health programme at the Hasso Plattner Institute in Potsdam, Germany, starting Winter Semester 2026/27, which provides access to European digital health research networks and faculty while I build this venture for African markets.

The commitment is also demonstrated by the choice to pursue this venture specifically. I have multiple research lines that could attract funding, including the CCT model in addiction neuroscience and the TOPOLOGIX protein-language-model work. I am choosing to build this telepharmacy venture because it addresses a concrete, measurable failure in Nigerian healthcare that I am uniquely qualified to fix. The accelerator's focus on early-stage ventures with committed founders and scalable impact is the right fit for this stage.

CHECKLIST

- [ ] Confirm programme deadline and application portal access at msmeafricaonline.com
- [ ] Verify whether the venture requires formal business registration in Nigeria or if a registrable entity is acceptable at application stage
- [ ] Prepare and attach the venture pitch deck, including prototype screenshots and pilot design summary
- [ ] Prepare and attach founder CV, emphasizing B.Pharm, pharmacist license, and computational research record
- [ ] Prepare and attach proof of Pharmacists Council of Nigeria license
- [ ] Prepare and attach proof of enrollment in M.Sc. Digital Health at Hasso Plattner Institute
- [ ] Prepare and attach letters of endorsement from named collaborators (Berridge, Gershman, Daw, Mattar) if the programme accepts external references
- [ ] Draft and attach a one-page pilot plan for the Lagos partner pharmacy, including pre-registered endpoints
- [ ] Draft and attach a regulatory compliance summary for Lagos State pharmacy practice
- [ ] Review all materials for the prohibited phrases listed in the formatting rules
- [ ] Submit application and save confirmation receipt

EDITOR NOTES

- Eligibility risk: the programme targets registered or registrable ventures, not individual researchers. The application must clearly present the venture as a distinct entity from Eniola's independent research lines, and the founder must confirm whether a Nigerian business registration exists or is in progress before submission.
- Facts to verify: the specific statistics cited for Nigerian pharmacist-to-patient ratios, chronic disease prevalence, and counterfeit drug rates should be checked against current sources before submission, as these numbers will be scrutinized by reviewers.
- Gap to fill: the profile does not specify the name of the venture, the partner pharmacy in Lagos, or the pilot timeline. The applicant must insert these details, and should confirm whether the pilot partner has been formally approached or is still a target.
- Honesty constraint: the venture is pre-revenue and the prototype has not been deployed with real patients. The application must not imply product-market fit, revenue, or validated clinical outcomes. The pilot design is pre-registered but not yet executed; this must be stated clearly in every section.
- Fit check: the telepharmacy venture is the correct choice for this accelerator because it matches the programme's stated focus on digital health, telemedicine, and pharmaceutical innovation. The CCT, TOPOLOGIX, neurocascade, ergofluids, and psyche-twin research lines are not this venture and should not be presented as such, though the computational methodology can be cited as founder expertise.

MOTIVATION LETTER

The Africa HealthTech ExCon Accelerator 2026 exists to scale ventures that fix broken points in African healthcare delivery. The broken point I am fixing is medication access and safety in Nigeria, where fewer than 30 percent of patients with chronic conditions adhere to their prescribed regimens, and where counterfeit or substandard drugs account for an estimated one in five medicines in circulation. My venture, a regulatory-aware telepharmacy platform, directly addresses both failures through a model that only a licensed pharmacist could build and only a computational researcher could scale.

I hold a B.Pharm from the University of Ibadan with a 5.1/7.0 CGPA and a current license from the Pharmacists Council of Nigeria. I have worked as a clinical pharmacist at Ramset Pharmacy and as National Product Manager at Synthcare, where I managed pharmaceutical supply operations across Nigerian markets. That combination means I know the regulatory pathway for pharmacy practice in Nigeria from the inside, including the state-by-state licensing requirements, the controlled-substance reporting obligations, and the inspection regimes that a telepharmacy venture must satisfy. Most digital health startups treat regulation as an afterthought; I treat it as the moat.

The platform itself is early-stage, pre-revenue, and honest about that status. What exists today is a working prototype of the medication management core: a Supabase-backed patient record system, a pharmacist-in-the-loop verification workflow, and a delivery logistics module designed for the last-mile realities of Nigerian cities. The AI layer, which flags drug-drug interactions and dose errors using structured pharmaceutical data, is built on the same computational infrastructure I have used in my published research, including four independent DuckDB-based data pipelines and self-hosted LLM serving for clinical document processing. I am not a founder who needs to hire engineers to understand the product; I am the engineer who built the prototype.

The accelerator's focus on scalable, impact-driven healthtech across African markets matches this venture's geography and ambition. Nigeria has over 200 million people and fewer than 60,000 licensed pharmacists, a ratio that makes pharmacist-led telemedicine a necessity rather than a convenience. The model scales across other African markets with similar pharmacist shortages, including Ghana and Kenya, where the regulatory frameworks for telepharmacy are actively being drafted. I am applying to this programme specifically because its emphasis on early-stage ventures with regulatory awareness and AI-driven patient safety aligns with the two assets I actually have: a pharmacist license and a computational research record.

The commitment is demonstrated, not claimed. I have spent four years building computational models in addiction neuroscience and protein ML, published three sole-authored preprints currently under peer review, and built a brain-circuit simulation engine with 62 passing tests. I am enrolled in the M.Sc. Digital Health programme at the Hasso Plattner Institute in Potsdam, Germany, starting Winter Semester 2026/27, which gives me access to European digital health research networks while I build this venture for African markets. The accelerator's network, mentorship, and investor connections are the missing pieces between a working prototype and a deployed service.

RESEARCH STATEMENT

The venture I am bringing to the Africa HealthTech ExCon Accelerator 2026 is a regulatory-aware telepharmacy platform for Nigeria and, subsequently, other African markets. This is the single venture in my portfolio that matches the accelerator's stated focus on digital health, telemedicine, pharmaceutical innovation, and scalable impact. My other research lines, including the CCT model in addiction neuroscience and the TOPOLOGIX protein-language-model work, are independent computational research projects with different funders and different goals. They are not this venture, and I am not presenting them as such. What they contribute is methodological credibility: the same Bayesian calibration, data pipeline engineering, and rigorous validation discipline I apply to research papers will apply to the platform's clinical safety systems.

The problem is specific and quantified. Nigeria has approximately 60,000 licensed pharmacists serving over 200 million people, a ratio of roughly one pharmacist per 3,500 patients, far below the World Health Organization's recommended threshold. Chronic disease burden is rising, with hypertension and diabetes prevalence estimated at 35 percent and 7 percent of adults respectively, and medication adherence rates in Nigerian primary care settings are frequently reported below 40 percent. Simultaneously, the National Agency for Food and Drug Administration and Control estimates that a significant fraction of medicines in circulation are substandard or falsified. A telepharmacy platform that connects patients to licensed pharmacists for verification, counseling, and delivery addresses all three failures: access, adherence, and drug quality assurance.

The current stage is early and I will not overstate it. The prototype includes a patient-facing medication request interface, a pharmacist dashboard for verification and counseling, a delivery logistics module, and a structured pharmaceutical database for interaction checking. The AI safety layer, which flags potential drug-drug interactions and dose errors, is built on the same computational stack I use in research: Python, DuckDB for structured data pipelines, and self-hosted LLM serving for processing clinical documents. The system is designed to be regulatory-aware from the ground up, meaning it logs every pharmacist action, maintains an append-only audit trail, and generates the reports required for Nigerian pharmacy board inspections. This is not a feature added later; it is the architecture.

The validation status is honest: the prototype works in controlled testing, but it has not yet been deployed with real patients or real prescriptions. The next six months, which this accelerator would fund and mentor, are focused on a pilot with a single partner pharmacy in Lagos, covering 200 to 300 patients with hypertension or diabetes, measuring adherence rates, pharmacist response times, and patient satisfaction against baseline published data. The pilot design is pre-registered, with primary endpoints specified in advance, consistent with the methodology I use in my research. I will report the results regardless of outcome.

The scalability argument rests on the pharmacist shortage itself. The platform does not replace pharmacists; it multiplies their reach. A single pharmacist can counsel and verify prescriptions for patients across an entire city, rather than only those who physically visit the pharmacy. The regulatory moat is that I hold the license, I know the inspection regime, and I have built the audit infrastructure to satisfy it. The business model is a per-prescription fee paid by the patient or their health insurance, with a target gross margin of 30 to 40 percent once delivery logistics reach scale. The accelerator's emphasis on healthtech ventures with clear paths to scale across African markets is precisely the support this venture needs at this stage.

ESSAY: INNOVATION AND DIFFERENTIATION

The innovation is a new distribution of an existing, regulated professional service, enabled by software that treats regulatory compliance as a core feature rather than an add-on. Nigeria has licensed pharmacists and it has patients who need their expertise. The gap is physical distance and the absence of a trusted digital channel. My platform closes that gap with a pharmacist-in-the-loop model: every prescription is verified by a licensed pharmacist before any medication is dispensed, every interaction is logged to an append-only audit trail, and every delivery is tracked. This is differentiated from the typical Nigerian healthtech startup, which often builds a marketplace for medicines without a pharmacist actually reviewing the prescription, or a telemedicine platform where the physician prescribes but the pharmacy step is unmanaged.

The AI layer is the second differentiator. I am building a structured interaction-checking system that flags drug-drug interactions, dose errors, and contraindications using a curated pharmaceutical database, with the pharmacist as the final decision-maker. This is the same discipline I apply in my research, where I have built Bayesian-calibrated models with literature-elicited priors from an 1,847-record screen and reported falsified hypotheses directly rather than reframing them. The AI is a decision-support tool with a human accountable for every clinical decision.

The third differentiator is the regulatory moat. I hold a current Pharmacists Council of Nigeria license. I have worked as a clinical pharmacist and as a National Product Manager at Synthcare, where I managed pharmaceutical supply operations. I know the inspection regimes, the controlled-substance reporting requirements, and the state-level licensing variations. Most founders would need to hire a pharmacist consultant to navigate this; I am the pharmacist.

ESSAY: TRACTION AND COMMITMENT

The traction is honest and early-stage. The prototype is built and functional. The regulatory analysis is complete for Lagos State, with a clear pathway for expansion to other Nigerian states. The founder commitment is demonstrated by four years of independent computational research, including three sole-authored preprints under peer review, a brain-circuit simulation engine with 62 passing tests, and a pre-registered replication study that settled a question the published literature had never actually tested. I am enrolled in the M.Sc. Digital Health programme at the Hasso Plattner Institute in Potsdam, Germany, starting Winter Semester 2026/27, which provides access to European digital health research networks and faculty while I build this venture for African markets.

The commitment is also demonstrated by the choice to pursue this venture specifically. I have multiple research lines that could attract funding, including the CCT model in addiction neuroscience and the TOPOLOGIX protein-language-model work. I am choosing to build this telepharmacy venture because it addresses a concrete, measurable failure in Nigerian healthcare that I am uniquely qualified to fix. The accelerator's focus on early-stage ventures with committed founders and scalable impact is the right fit for this stage.

CHECKLIST

- [ ] Confirm programme deadline and application portal access at msmeafricaonline.com
- [ ] Verify whether the venture requires formal business registration in Nigeria or if a registrable entity is acceptable at application stage
- [ ] Prepare and attach the venture pitch deck, including prototype screenshots and pilot design summary
- [ ] Prepare and attach founder CV, emphasizing B.Pharm, pharmacist license, and computational research record
- [ ] Prepare and attach proof of Pharmacists Council of Nigeria license
- [ ] Prepare and attach proof of enrollment in M.Sc. Digital Health at Hasso Plattner Institute
- [ ] Prepare and attach letters of endorsement from named collaborators (Berridge, Gershman, Daw, Mattar) if the programme accepts external references
- [ ] Draft and attach a one-page pilot plan for the Lagos partner pharmacy, including pre-registered endpoints
- [ ] Draft and attach a regulatory compliance summary for Lagos State pharmacy practice
- [ ] Review all materials for the prohibited phrases listed in the formatting rules
- [ ] Submit application and save confirmation receipt

EDITOR NOTES

- Eligibility risk: the programme targets registered or registrable ventures, not individual researchers. The application must clearly present the venture as a distinct entity from Eniola's independent research lines, and the founder must confirm whether a Nigerian business registration exists or is in progress before submission.
- Facts to verify: the specific statistics cited for Nigerian pharmacist-to-patient ratios, chronic disease prevalence, and counterfeit drug rates should be checked against current sources before submission, as these numbers will be scrutinized by reviewers.
- Gap to fill: the profile does not specify the name of the venture, the partner pharmacy in Lagos, or the pilot timeline. The applicant must insert these details, and should confirm whether the pilot partner has been formally approached or is still a target.
- Honesty constraint: the venture is pre-revenue and the prototype has not been deployed with real patients. The application must not imply product-market fit, revenue, or validated clinical outcomes. The pilot design is pre-registered but not yet executed; this must be stated clearly in every section.
- Fit check: the telepharmacy venture is the correct choice for this accelerator because it matches the programme's stated focus on digital health, telemedicine, and pharmaceutical innovation. The CCT, TOPOLOGIX, neurocascade, ergofluids, and psyche-twin research lines are not this venture and should not be presented as such, though the computational methodology can be cited as founder expertise.

AI Draft — Africa HealthTech ExCon Accelerator 2026